[Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex<sup>®</sup> for patients with premenopausal breast cancer].

Xinyu Shao(Qingdao University), Zefei Jiang, M. LI(Dalian Medical University), Guibin Qiao(St James's University Hospital), Jian‐Yun Nie(Renmin University of China), Jingfang Wang(Shanxi Medical University), Zhaofeng Niu, Qiao Cheng(Medical College of Wisconsin), Jianxi Ou(Xinjiang Medical University), David Ziyou Chen(Anhui Medical University), X J Wang(Zhejiang Cancer Hospital), Meng Cui(Jilin University of Chemical Technology), Jun Huang(Fujian Medical University), L L Chen(First Affiliated Hospital of Xiamen University), Y S Wang(Shandong Tumor Hospital), Rong Luo(Cangzhou Central Hospital), Hui Li(China-Japan Friendship Hospital), Ting Sun(China University of Petroleum, Beijing), Qinxin Zhang(Nanjing Maternity and Child Health Care Hospital), Aimin Zang, Zhengbiao Ouyang(Shenzhen University), Shiming Yang(Ministry of Education of the People's Republic of China), Qiang Liu, Yao Yao(Zhejiang Sci-Tech University), Jian Zhang(Texas A&M University), Jian Yang(Westlake University), Jiawen Wang(Hubei University of Science and Technology), Ziqi Chen(The University of Melbourne), Hong Zhao(McGill University), Enxiang Zhou(Central South University), Pingzhi Fan(Southwest Jiaotong University), Jingguo Wang(The University of Texas at Arlington), Yumei Ding(Yunnan Agricultural University), Rongrong Yang(Soochow University), L Y Qian(Central South University), Weiwei Su(Inner Mongolia Medical University), Yue Teng(Heilongjiang Bayi Agricultural University)
Cited by 0


Related Papers